GO:0062133 negative regulation of L-glutamine biosynthetic process: Metabolic Control, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0062133 describes any process that stops, prevents, or reduces the frequency, rate, or extent of L-glutamine biosynthesis.
• L-glutamine biosynthesis is a central metabolic node, and its negative regulation is critical for adapting to nutrient availability and cellular stress [1, 4].
• Key regulators include metabolic enzymes such as GAPDH, SIRT5, and DYRK1A, which integrate glycolytic and mitochondrial signals to suppress glutamine production [2, 6, 7].
• Dysregulation of this process is implicated in cancer progression, immune cell function, and metabolic disorders such as psoriasis [1, 2, 6, 8].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of the regulatory mechanisms controlling L-glutamine biosynthesis.
• Understanding GO:0062133 provides a foundation for therapeutic strategies targeting metabolic vulnerabilities in cancer and inflammatory diseases [3, 4, 7].
Description
L-glutamine is the most abundant free amino acid in the human body and serves as a critical nitrogen donor and carbon source for biosynthetic pathways [1, 4]. The biosynthetic process that produces L-glutamine is tightly controlled, and its negative regulation—captured by the Gene Ontology term GO:0062133—ensures that glutamine levels are matched to cellular demand. This regulation is essential for maintaining metabolic homeostasis, and its disruption is associated with diseases ranging from cancer to autoimmune conditions [1, 6, 8]. Researchers studying this process aim to identify the molecular players that suppress glutamine synthesis and to understand how these players are integrated into broader metabolic signaling networks [2, 4, 7]. Recent studies have highlighted that negative regulation of L-glutamine biosynthesis is not a passive event but an active, signal-dependent process involving post-translational modifications and transcriptional control [2, 6, 7]. For example, the glycolytic enzyme GAPDH can be modified by serotonylation, which couples glycolytic flux to glutamine metabolism in CD8+ T cells. Similarly, loss of the mitochondrial deacetylase SIRT5 rewires glutamine metabolism to promote pancreatic cancer progression. These findings underscore the importance of GO:0062133 in both normal physiology and disease. This article provides a comprehensive overview of the negative regulation of L-glutamine biosynthetic process, covering its definition, key genes, regulatory mechanisms, disease relevance, and experimental approaches for study.
negative regulation of L-glutamine biosynthetic process At A Glance
| GO ID | GO:0062133 |
|---|---|
| GO term | negative regulation of L-glutamine biosynthetic process |
| Ontology | biological_process |
| Synonym | None |
| Major function | Suppression of L-glutamine production in response to metabolic signals |
| Related processes | Regulation of amino acid metabolism, nitrogen homeostasis, mTOR signaling |
| Key regulators | GAPDH, SIRT5, DYRK1A, SLC38A5 |
| Disease relevance | Cancer, immune disorders, metabolic syndromes |
What Is GO:0062133?
GO:0062133, negative regulation of L-glutamine biosynthetic process, is defined as any biological process that stops, prevents, or reduces the frequency, rate, or extent of L-glutamine biosynthesis. In other words, it encompasses all molecular events—such as enzyme inhibition, transcriptional repression, or degradation of biosynthetic enzymes—that lead to a decrease in the production of L-glutamine from its precursors. This term is a child of 'negative regulation of biosynthetic process' and 'regulation of L-glutamine metabolic process'.
Why Is negative regulation of L-glutamine biosynthetic process Important in Cell Biology?
The negative regulation of L-glutamine biosynthesis is vital for cellular adaptation to fluctuating nutrient availability and stress. Glutamine serves as a key substrate for nucleotide synthesis, glutathione production, and anaplerosis, and its overproduction can fuel pathological cell proliferation [1, 6]. Conversely, insufficient glutamine can impair immune function and redox balance [2, 4]. Thus, understanding how cells suppress glutamine biosynthesis is essential for deciphering metabolic reprogramming in cancer, inflammation, and metabolic diseases [3, 7, 8].
• Maintains metabolic homeostasis by preventing excessive glutamine accumulation [1, 4].
• Regulates immune cell function, including CD8+ T cell antitumor immunity.
• Modulates cancer cell proliferation and survival, particularly in pancreatic and hepatocellular carcinomas [6, 7].
• Influences ferroptosis sensitivity and chemotherapy resistance.
• Integrates with cholesterol synthesis and other biosynthetic pathways.
• Contributes to stress-induced anxiety and parental behavior via hypothalamic circuits.
• Alters amino acid profiles in inflammatory skin diseases like psoriasis.
• Provides targets for therapeutic intervention in metabolic disorders [1, 3].
What Happens During negative regulation of L-glutamine biosynthetic process?
Signal Sensing and Integration
In simple terms: Cells first detect changes in nutrient levels or stress, which triggers a response to adjust glutamine production.
Negative regulation of L-glutamine biosynthesis begins with the sensing of metabolic cues such as amino acid availability, energy status, and oxygen levels. Key sensors include mTORC1 and the integrated stress response (ISR), which respond to glutamine levels and other inputs. For instance, glutamine sensing licenses cholesterol synthesis through a mechanism that involves the sterol regulatory element-binding protein (SREBP) pathway. In immune cells, serotonylation of GAPDH couples glycolytic metabolism to glutamine regulation, linking neurotransmitter signaling to metabolic control.
Transcriptional and Post-translational Control
In simple terms: Once a signal is received, cells can reduce the production of enzymes needed to make glutamine or modify these enzymes to make them less active.
Transcriptional repression of glutamine biosynthetic genes, such as GLUL (glutamine synthetase), can reduce enzyme abundance. Post-translational modifications, including acetylation and phosphorylation, directly modulate enzyme activity. SIRT5, a mitochondrial deacetylase, regulates glutamine metabolism by removing acetyl groups from key enzymes; its loss leads to metabolic rewiring that promotes pancreatic cancer. Similarly, DYRK1A phosphorylates targets that affect oxidative phosphorylation and glutamine utilization in hepatocellular carcinoma.
Enzymatic Inhibition and Feedback Loops
In simple terms: The enzymes that actually build glutamine can be temporarily blocked or turned off by molecules that signal 'enough glutamine'.
Feedback inhibition by glutamine itself or by downstream metabolites can directly inhibit glutamine synthetase activity. Additionally, proteins like GAPDH can bind to and inhibit glutamine synthetase under specific conditions. The solute carrier SLC38A5 modulates glutamine transport and metabolism, indirectly affecting biosynthesis through substrate availability.
Integration with Cellular Metabolism
In simple terms: The decision to stop making glutamine is connected to other metabolic pathways, so the cell can balance all its needs.
Negative regulation of glutamine biosynthesis is intertwined with glycolysis, the TCA cycle, and lipid synthesis. Succinate, a TCA cycle intermediate, can act as an inflammatory signal that induces IL-1β through HIF-1α, linking glutamine metabolism to immune responses. In psoriasis, metabolomic profiling reveals alterations in amino acid and carnitine levels, suggesting that glutamine regulation is part of a broader metabolic signature.
Key Genes Involved in GO:0062133 negative regulation of L-glutamine biosynthetic process
The following genes and proteins have been experimentally linked to the negative regulation of L-glutamine biosynthetic process or its associated metabolic pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GAPDH | Glycolytic enzyme; serotonylation modulates glutamine metabolism | Links glycolysis to immune cell function |
| SIRT5 | Mitochondrial deacetylase; regulates glutamine metabolism | Loss promotes pancreatic cancer progression |
| DYRK1A | Kinase; affects OXPHOS and glutamine utilization | Determines sensitivity to OXPHOS inhibition in HCC |
| SLC38A5 | Amino acid transporter; modulates glutamine uptake | Influences ferroptosis and gemcitabine resistance |
| GLUL | Glutamine synthetase; catalyzes glutamine biosynthesis | Direct target of negative regulation |
| HIF-1α | Transcription factor; induced by succinate | Links glutamine metabolism to inflammation |
| mTORC1 | Nutrient sensor; regulates glutamine metabolism | Central to metabolic homeostasis |
| SREBP | Transcription factor; cholesterol synthesis | Glutamine sensing licenses cholesterol synthesis |
| IL-1β | Pro-inflammatory cytokine | Induced by succinate via HIF-1α |
| CD8+ T cells | Immune cells; rely on glutamine metabolism | GAPDH serotonylation affects antitumor immunity |
| Kras | Oncogene; drives metabolic rewiring | SIRT5 loss promotes Kras-induced pancreatic cancer |
| OXPHOS complex | Mitochondrial oxidative phosphorylation | DYRK1A-TGF-β axis determines sensitivity |
| SLC1A5 | Glutamine transporter | Often co-regulated with glutamine metabolism |
| GLS | Glutaminase; converts glutamine to glutamate | Opposes glutamine biosynthesis |
| GDH | Glutamate dehydrogenase | Links glutamine metabolism to TCA cycle |
| PSAT1 | Phosphoserine aminotransferase | Involved in serine synthesis, interconnected with glutamine |
| MTHFD2 | Mitochondrial enzyme in one-carbon metabolism | Supports purine synthesis, linked to glutamine |
How Is negative regulation of L-glutamine biosynthetic process Regulated?
The negative regulation of L-glutamine biosynthesis is controlled by multiple signaling pathways. mTORC1 senses glutamine levels and other nutrients to coordinate cell growth with glutamine availability. The integrated stress response (ISR) can suppress glutamine synthesis under amino acid deprivation. Post-translational modifications, such as acetylation by SIRT5 and phosphorylation by DYRK1A, directly modulate enzyme activities [6, 7]. Additionally, GAPDH serotonylation provides a link between neurotransmitter signaling and glutamine metabolism in T cells. These regulatory layers ensure that glutamine production is finely tuned to cellular needs.
negative regulation of L-glutamine biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SIRT5 | Pancreatic cancer progression | KO and overexpression in pancreatic cancer cell lines |
| DYRK1A | Hepatocellular carcinoma, OXPHOS sensitivity | Point mutation and KO in HCC models |
| SLC38A5 | Pancreatic cancer, ferroptosis, gemcitabine resistance | Knockout and overexpression in pancreatic cancer cells |
| GAPDH | Antitumor immunity, CD8+ T cell function | Knock-in of serotonylation site mutants |
| GLUL | Metabolic disorders, hyperammonemia | Knockout and knock-in in hepatocytes |
Cancer Metabolism and Progression
Dysregulation of glutamine metabolism is a hallmark of many cancers. Loss of SIRT5 promotes Kras-induced pancreatic cancer progression by rewiring glutamine metabolism. In hepatocellular carcinoma, the DYRK1A-TGF-β signaling axis determines sensitivity to OXPHOS inhibition, implicating glutamine regulation in therapeutic response. SLC38A5 modulates ferroptosis and gemcitabine resistance in pancreatic cancer, highlighting the role of glutamine transporters in chemoresistance.
Immune Function and Inflammation
Glutamine metabolism is critical for immune cell function. GAPDH serotonylation couples glycolytic metabolism to antitumor immunity in CD8+ T cells, affecting their effector functions. Succinate, a TCA cycle intermediate, acts as an inflammatory signal that induces IL-1β through HIF-1α, linking glutamine metabolism to inflammation.
Metabolic and Inflammatory Skin Diseases
Metabolomic profiling in psoriasis reveals alterations in amino acid and carnitine levels, suggesting that glutamine metabolic pathways are perturbed in inflammatory skin conditions.
Neurological and Behavioral Disorders
The medial preoptic area antagonistically mediates stress-induced anxiety and parental behavior, and metabolic pathways including glutamine may influence these processes.
From negative regulation of L-glutamine biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SIRT5 affect glutamine biosynthesis? | SIRT5 knockout cell lines |
| How does DYRK1A phosphorylation regulate glutamine metabolism? | DYRK1A point mutant knock-in |
| What is the role of GAPDH serotonylation in T cell immunity? | GAPDH serotonylation-site knock-in mice |
| Can SLC38A5 overexpression overcome gemcitabine resistance? | SLC38A5 overexpression in pancreatic cancer cells |
| Does glutamine sensing regulate cholesterol synthesis? | mTORC1 knockout and SREBP reporter models |
| How does succinate induce IL-1β via HIF-1α? | HIF-1α knockout macrophages |
How to Study the negative regulation of L-glutamine biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Quantification of glutamine and related metabolites | Profiling metabolic changes in disease models |
| 13C-glutamine tracing | Flux through glutamine biosynthetic and catabolic pathways | Assessing pathway activity |
| RNA-seq | Transcriptional changes in metabolic genes | Identifying regulators of glutamine biosynthesis |
| Proteomics | Protein abundance and post-translational modifications | Detecting acetylation or serotonylation |
| CRISPR knockout screen | Genes required for glutamine regulation | Discovery of novel regulators |
| Western blot | Protein expression and modification status | Validating specific gene effects |
| Fluorescent biosensors | Real-time glutamine levels | Live-cell imaging of metabolism |
| Seahorse assay | Mitochondrial respiration and glycolysis | Linking glutamine metabolism to OXPHOS |
Metabolomics and Flux Analysis
Metabolomic profiling, including LC-MS and GC-MS, can quantify glutamine and related metabolites to assess changes in biosynthesis. Stable isotope tracing with 13C-glutamine or 15N-glutamine allows flux analysis through biosynthetic pathways.
Transcriptomics and Proteomics
RNA-seq can identify transcriptional changes in glutamine biosynthetic genes, while proteomics can reveal post-translational modifications on enzymes like GAPDH and SIRT5 [2, 6].
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout screens can identify genes that negatively regulate glutamine biosynthesis. Focused screens targeting metabolic enzymes are also valuable [3, 7].
Imaging and Reporter Assays
Fluorescent reporters for glutamine levels or biosensor-based imaging can visualize real-time changes in glutamine metabolism in live cells.
How CRISPR Can Be Used to Study GO:0062133 negative regulation of L-glutamine biosynthetic process
Knockout
CRISPR knockout of candidate genes such as SIRT5 or DYRK1A can reveal their role in suppressing glutamine biosynthesis. For example, SIRT5 knockout in pancreatic cancer cells leads to metabolic rewiring and altered glutamine metabolism.
Point Mutation
Introducing point mutations in enzymes like GAPDH to prevent serotonylation can test the importance of specific post-translational modifications in regulating glutamine metabolism.
Knock-in
Knock-in of tagged versions of glutamine biosynthetic enzymes (e.g., GLUL-HA) allows for affinity purification and interaction studies, revealing regulatory complexes.
Overexpression
Overexpression of SLC38A5 or other transporters can model increased glutamine uptake and its impact on ferroptosis and chemoresistance.
How EDITGENE Supports negative regulation of L-glutamine biosynthetic process Research
Researchers studying negative regulation of L-glutamine biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in suppressing glutamine production or is merely correlated with metabolic changes. Precise genetic models are essential to establish causality and to dissect the molecular mechanisms.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of L-glutamine biosynthetic process research.
Frequently Asked Questions About negative regulation of L-glutamine biosynthetic process
What is GO:0062133?
GO:0062133 is the Gene Ontology term for negative regulation of L-glutamine biosynthetic process, describing any process that stops, prevents, or reduces the rate of L-glutamine production.
What genes are involved in negative regulation of L-glutamine biosynthetic process?
Key genes include GAPDH, SIRT5, DYRK1A, SLC38A5, and GLUL, among others [2, 3, 6, 7].
How is L-glutamine biosynthesis regulated?
It is regulated by nutrient sensors like mTORC1, post-translational modifications, and feedback inhibition [4, 6].
Why is negative regulation of L-glutamine biosynthesis important in cancer?
It helps control glutamine availability for tumor growth; dysregulation can promote cancer progression and therapy resistance [6, 7].
What diseases are associated with dysregulated glutamine biosynthesis?
Cancer, inflammatory diseases like psoriasis, and immune disorders [1, 6, 8].
How can I study negative regulation of L-glutamine biosynthesis?
Using CRISPR knockout, point mutation, knock-in, overexpression models, combined with metabolomics and flux analysis [2, 3, 4].
What is the role of SIRT5 in glutamine metabolism?
SIRT5 is a mitochondrial deacetylase that regulates glutamine metabolism; its loss promotes pancreatic cancer.
How does GAPDH regulate glutamine biosynthesis?
GAPDH serotonylation couples glycolytic metabolism to glutamine regulation in CD8+ T cells.
What is the connection between glutamine and cholesterol synthesis?
Glutamine sensing licenses cholesterol synthesis through a mechanism involving SREBP.
Can CRISPR be used to study glutamine biosynthesis?
Yes, CRISPR knockout, knock-in, and overexpression models are powerful tools to dissect regulatory mechanisms [3, 7].
Conclusion
The negative regulation of L-glutamine biosynthetic process (GO:0062133) is a critical metabolic control point that integrates nutrient sensing, post-translational modifications, and transcriptional programs. Its dysregulation contributes to cancer, immune dysfunction, and metabolic diseases. By leveraging CRISPR-based models and advanced metabolomic techniques, researchers can uncover new regulators and therapeutic targets within this pathway.
References
- 1. Tannahill GM et al.. 2013. Succinate is an inflammatory signal that induces IL-1β through HIF-1α.. Nature 496(7444):238-42 PMID: 23535595
- 2. Wang X et al.. 2024. A GAPDH serotonylation system couples CD8(+) T cell glycolytic metabolism to antitumor immunity.. Mol Cell 84(4):760-775.e7 PMID: 38215751
- 3. Kim MJ et al.. 2023. SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer.. Cells 12(20) PMID: 37887353
- 4. Garcia BM et al.. 2024. Glutamine sensing licenses cholesterol synthesis.. EMBO J 43(23):5837-5856 PMID: 39433901
- 5. Zhang GW et al.. 2021. Medial preoptic area antagonistically mediates stress-induced anxiety and parental behavior.. Nat Neurosci 24(4):516-528 PMID: 33526942
- 6. Hu T et al.. 2021. Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression.. Gastroenterology 161(5):1584-1600 PMID: 34245764
- 7. Cao Y et al.. 2025. DYRK1A-TGF-β signaling axis determines sensitivity to OXPHOS inhibition in hepatocellular carcinoma.. Dev Cell 60(10):1483-1497.e7 PMID: 39798576
- 8. Chen C et al.. 2021. Metabolomic profiling reveals amino acid and carnitine alterations as metabolic signatures in psoriasis.. Theranostics 11(2):754-767 PMID: 33391503
